Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Master Protocol In Metastatic Breast Cancer Likely In The Works

This article was originally published in The Pink Sheet Daily

Executive Summary

Oct. 21 public workshop cosponsored by prominent oncology groups will discuss international genomically driven trial to test multiple agents in metastatic breast cancer.

You may also be interested in...



Research Consortia Need Funding, But FDA Is More “Honest Broker”

FDA wants data standards in place so the increasingly popular clinical research collaborations can continue growing, but a researcher states that government also could make funding available to sustain the consortia.

Lung-MAP Patient Screening Should Translate To Cost-Savings

Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.

Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta

I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077572

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel